Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEBSep 14, 2024 · Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks; ponsegromab was generally considered safe and well-tolerated at all dose levels i At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms ...
New cancer cachexia treatment boosts weight gain and patient …
WEB1 day ago · Scientists discovered that a drug, ponsegromab, blocks a hormone known as GDF-15 that regulates appetite and body weight. The patients in the trial had elevated levels of GDF-15, a primary driver ...
Inhibition of GDF-15 with Ponsegromab Results in Increased Weight
WEB1 day ago · In a randomised phase II study involving patients with cancer cachexia and an elevated growth differentiation factor 15 (GDF-15) level, the inhibition of GDF-15 with ponsegromab resulted in a significant, robust increase in body weight at 12 weeks, as compared with placebo. In addition, patients in the …
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEB6 days ago · Pfizer Inc. today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15, met its primary endpoint of change from baseline in body ...
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab
WEB6 days ago · Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose...
New therapy shows promise in improving appetite, quality of life …
WEB5 days ago · Ponsegromab was made to target a hormone and protein often elevated in people with cancer called growth differentiation factor 15, or GDF-15. This clinical trial demonstrated that GDF-15 inhibition with ponsegromab improved body weight, symptoms and overall activity in patients with cancer cachexia and …
Pfizer says its experimental drug for deadly condition that causes ...
WEBSep 14, 2024 · Pfizer ’s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said ...
Novel Agent Effective for Cancer Wasting Disorder
WEB2 days ago · The study's primary endpoint was weight gain at week 12, analyzed with a Bayesian hierarchical Emax model. Each dose level of ponsegromab resulted in significant improvements, with the following ...
Ponsegromab for the Treatment of Cancer Cachexia
WEB6 days ago · In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and...
Pfizer Highlights Diverse Oncology Portfolio and Combination …
WEBSep 11, 2024 · Two late-breaking presentations include longer-term results from BRAFTOVI ® + MEKTOVI ® PHAROS study in BRAF V600E-mutant metastatic NSCLC and new Phase 2 ponsegromab data in cancer cachexia; Encouraging early results for PD-L1 vedotin ADC, disitamab vedotin and the novel combination of CDK4 + CDK2 inhibitors highlight rapidly advancing pipeline
- Some results have been removed